For example, the ability of endothelium-derived CNP to regulate coronary vascular reactivity, coupled to its pronounced effect on leucocyte flux, platelet function and atheroma,1 suggests mimicking CNP bioactivity pharmacologically is likely to be an effective means by which to slow the progression of coronary artery disease. The gene discussed is CNP; the disease is coronary artery disorder.